azacitidine

The drug is prescribed to adult patients who are not candidates for stem cell transplantation for the treatment of myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML).

Form: powder for injection suspension

ATC: L01BC07

Manufacturer: Intas Pharmaceuticals Limited (manufacturing of medicinal product, primary and secondary packaging)

The drug is intended for the treatment of adult patients who are not candidates for stem cell transplantation, for the following diseases: intermediate and high-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) with a certain blast content in the bone marrow, as well as acute myeloid leukemia (AML).

Form: powder for injection suspension

ATC: L01BC07

Manufacturer: Intas Pharmaceuticals Limited (manufacturing of medicinal product, primary and secondary packaging)

The drug is intended for the treatment of adult patients with certain subtypes of myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML).

Form: powder for injection solution

ATC: L01BC07

Manufacturer: MSN Laboratories Private Limited

The drug is intended for the treatment of adult patients who are not candidates for stem cell transplantation, for the following diseases: intermediate-2 and high-risk myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML).

Form: lyophilisate for solution for injection

ATC: L01BC07

Manufacturer: Shilpa Medicare Limited (full production cycle; quality control and stability testing (physical and chemical tests))

The drug is intended for adult patients who are ineligible for stem cell transplantation and suffer from intermediate-2 and high-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) with 10–29% blasts in the bone marrow, as well as acute myeloid leukemia (AML) with varying blast levels (20–30% or over 30% depending on the classification).

Form: lyophilisate for solution for injection

ATC: L01BC07

Manufacturer: Nang Quang Pharmaceutical Co. Ltd.

The drug is intended for the treatment of adult patients with intermediate-2 and high-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) in certain clinical cases where stem cell transplantation is not possible.

Form: lyophilisate for solution for injection

ATC: L01BC07

Manufacturer: Panacea Biotek Pharma Ltd.